title: Minimal Residual Disease as a Potential Surrogate End Point-Lingering Questions.
authors.affiliation: Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Nicole J
authors.initials: NJ
authors.lastname: Gormley
authors.affiliation: Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Ann T
authors.initials: AT
authors.lastname: Farrell
authors.affiliation: Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Richard
authors.initials: R
authors.lastname: Pazdur
mesh_terms: D015415:Biomarkers; D018572:Disease-Free Survival; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy / Q000473:pathology*; D018365:Neoplasm, Residual / Q000473:pathology*
chemical_list: D015415:Biomarkers